Page 51 - AN-3-1

Advanced Neurology Antibodies as neurodegenerative biomarkers

143. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized early Alzheimer’s disease with lecanemab, an anti-Aβ
phase 3 studies of aducanumab in early Alzheimer’s disease. protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
J Prev Alzheimers Dis. 2022;9(2):197-210.
doi: 10.1186/s13195-021-00813-8
doi: 10.14283/jpad.2022.30
154. McDade E, Cummings JL, Dhadda S, et al. Lecanemab in
144. Sevigny J, Chiao P, Bussière T, et al. The antibody patients with early Alzheimer’s disease: Detailed results
aducanumab reduces Aβ plaques in Alzheimer’s disease. on biomarker, cognitive, and clinical effects from the
Nature. 2016;537(7618):50-56. randomized and open-label extension of the phase 2 proof-
doi: 10.1038/nature19323 of-concept study. Alzheimers Res Ther. 2022;14(1):191.
145. Ferrero J, Williams L, Stella H, et al. First-in-human, double- doi: 10.1186/s13195-022-01124-2
blind, placebo-controlled, single-dose escalation study of 155. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced
aducanumab (BIIB037) in mild-to-moderate Alzheimer’s anti-β-amyloid (Aβ) antibody with unique Aβ binding
disease. Alzheimers Dement (N Y). 2016;2(3):169-176. properties promotes neuroprotection and glial engulfment
doi: 10.1016/j.trci.2016.06.002 of Aβ. J Neurosci. 2012;32(28):9677-9689.
146. Vaz M, Silva V, Monteiro C, Silvestre S. Role of aducanumab doi: 10.1523/JNEUROSCI.4742-11.2012
in the treatment of Alzheimer’s disease: Challenges and 156. Ultsch M, Li B, Maurer T, et al. Structure of crenezumab
opportunities. Clin Interv Aging. 2022;17:797-810. complex with aβ shows loss of β-hairpin. Sci
doi: 10.2147/CIA.S325026 Rep. 2016;6(1):39374.
147. Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related doi: 10.1038/srep39374
imaging abnormalities in 2 phase 3 studies evaluating 157. Yang T, Dang Y, Ostaszewski B, et al. Target engagement in
aducanumab in patients with early Alzheimer disease. an Alzheimer trial: Crenezumab lowers amyloid β oligomers
JAMA Neurol. 2022;79(1):13-21. in cerebrospinal fluid. Ann Neurol. 2019;86(2):215-224.
doi: 10.1001/jamaneurol.2021.4161 doi: 10.1002/ana.25513
148. Day GS, Scarmeas N, Dubinsky R, et al. Aducanumab 158. Cummings JL, Cohen S, van Dyck CH, et al. ABBY: A phase
use in symptomatic alzheimer disease evidence in focus. 2 randomized trial of crenezumab in mild to moderate
Neurology. 2022;98(15):619-631. Alzheimer disease. Neurology. 2018;90(21):e1889-e1897.
doi: 10.1212/WNL.0000000000200176 doi: 10.1212/wnl.0000000000005550
149. Tucker S, Möller C, Tegerstedt K, et al. The murine Version 159. Tariot PN, Lopera F, Langbaum JB, et al. The Alzheimer’s
of BAN2401 (mAb158) selectively reduces amyloid-β Prevention Initiative Autosomal-Dominant Alzheimer’s
protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Disease Trial: A study of crenezumab versus placebo in
Mice. J Alzheimers Dis. 2015;43(2):575-588. preclinical PSEN1 E280A mutation carriers to evaluate
doi: 10.3233/JAD-140741 efficacy and safety in the treatment of autosomal-dominant
Alzheimer’s disease, including a placebo-treated noncarrier
150. Dhadda S, Kanekiyo M, Li D, et al. Consistency of efficacy cohort. Alzheimers Dement (N Y). 2018;4:150-160.
results across various clinical measures and statistical
methods in the lecanemab phase 2 trial of early Alzheimer’s doi: 10.1016/j.trci.2018.02.002
disease. Alzheimers Res Ther. 2022;14(1):182. 160. Armour KL, Van De Winkel JGJ, Williamson LM,
doi: 10.1186/s13195-022-01129-x ClarkM. Differential binding to human FcgammaRIIa
and FcgammaRIIb receptors by human IgG wildtype and
151. Tahami Monfared AA, Tafazzoli A, Chavan A, et al. The mutant antibodies. Mol Immunol. 2003;40(9):585-593.
potential economic value of lecanemab in patients with
early Alzheimer’s disease using simulation modeling. Neurol doi: 10.1016/j.molimm.2003.08.004
Ther. 2022;11(3):1285-1307. 161. Landen JW, Andreasen N, Cronenberger CL, et al.,
doi: 10.1007/s40120-022-00373-5 Ponezumab in mild-to-moderate Alzheimer’s disease:
Randomized phase II PET-PIB study. Alzheimers Dement
152. Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A,
Zhang Q. Long-term health outcomes of lecanemab in (N Y). 2017;3(3):393-401.
patients with early Alzheimer’s disease using simulation doi: 10.1016/j.trci.2017.05.003
modeling. Neurol Ther. 2022;11(2):863-880.
162. Landen JW, Cohen S, Billing CB Jr, et al. Multiple-dose
doi: 10.1007/s40120-022-00350-y ponezumab for mild-to-moderate Alzheimer’s disease: Safety
and efficacy. Alzheimers Dement (N Y). 2017;3(3):339-347.
153. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized,
double-blind, phase 2b proof-of-concept clinical trial in doi: 10.1016/j.trci.2017.04.003

Volume 3 Issue 1 (2024) 16 https://doi.org/10.36922/an.2058